A clinical-stage biopharmaceutical company developing novel, transformative medicines for people living with psychiatric and neurological conditions.
The client was focused on critical-path aspects surrounding development and launch of their lead candidate in its lead indication, but had relatively little internal priority on the life-cycle-management and portfolio strategy that would ensure long-term growth and/or maximum valuation if they were to be acquired post-launch.
We identified and assessed commercially-viable opportunities that could be addressed by either in-house early-stage therapeutic candidates or sourced externally via in-licensing or bolt-on acquisitions. Deliverable components for each indication of interest included market overviews, competitive context, aspirational TPPs, and topline revenue forecasts.
Towards the conclusion of the project, the client announced its first bolt-on acquisition encompassing novel therapeutic candidates positioned to address indications assessed in our project work.
Our US VAO group is now involved in HEOR work of their lead program, including support of their ICER review.